Ironwood Pharmaceuticals has reported revenue of $10.24m for the first quarter ended 31 March 2011, as compared to $8.84m for the same period in 2010.
Subscribe to our email newsletter
The company has reported a net loss of $18.4m, compared to net loss of $16.25m, for the same period last year.
The company’s loss from operations was $18.54m, as compared to $14.5m for the same period prior year.
Ironwood said it will continue to advance its pipeline, which includes product candidates and research efforts focused on gastrointestinal disease, pain and inflammation, respiratory and allergic disease, and cardiovascular disease.
Based on its current operating plan, Ironwood continues to target ending fiscal year 2011 with greater than $150m of cash, cash equivalents, and available-for-sale securities.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.